India sends USD 2 million in medical aid to Nepal under Neighbourhood First Policy
New Delhi: India on Friday reaffirmed its commitment to the
Neighbourhood First Policy
by sending USD 2 million worth of medical aid to Nepal.
The assistance includes medicines and vaccines for patients with Thalassemia and Sickle Cell Disease. The first tranche of this aid consists of 17,030 vials of vaccines for the immunisation of Thalassemia patients.
Sharing a post on X, Ministry of External Affairs spokesperson Randhir Jaiswal wrote, "Reaffirming India's commitment to Neighbourhood First Policy. India sends assistance consisting of medicines and vaccines for patients with Thalassemia and Sickle Cell Disease worth $2 million, responding to a request from Nepal."
The post added, "The 1st tranche of 17,030 vials of Vaccines for Immunisation of patients with Thalassemia was handed over to Nepal."
Reaffirming 's commitment to #NeighbourhoodFirst Policy. sends assistance consisting of medicines and vaccines for patients with Thalassemia and Sickle Cell Disease worth $2 million, responding to a request from Nepal.The 1st tranche of 17,030 vials of Vaccines for... pic.twitter.com/KEEmFT6pia - Randhir Jaiswal (@MEAIndia) April 25, 2025
The Neighbourhood First policy guides the management of India's relations with countries in its immediate neighbourhood, focuses on creating mutually beneficial, people-oriented, regional frameworks for stability and prosperity, including through the building of physical, digital and people-to-people connectivity.
India engages with these countries on a consultative, non-reciprocal and outcome-oriented basis, driven by the principles of Samman (respect), Samvad (dialogue), Shanti (peace), and Samriddhi (prosperity).
As part of India's Neighbourhood First policy, the Government has been extending necessary developmental assistance and capacity-building initiatives, as per the needs and aspirations of the neighbouring countries, thereby contributing towards the holistic economic development of their countries.
Under this approach, India has been assisting neighbouring countries in the development of infrastructure projects ranging from large-scale infrastructure to community-related provisioning of assets and platforms, augmentation of capabilities and extending financial, budgetary and humanitarian assistance.
India's assistance under its Neighbourhood First policy is regarded as valuable by diverse sections of public opinion among our neighbours, ensuring a sustainable basis for these assistance programs to continue despite changes in administration in these countries.
Government keeps a vigilant watch on all developments which have a bearing on India's national security and takes all necessary measures to safeguard it.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
28 minutes ago
- Business Standard
Zydus Lifesciences receives USFDA tentative approval for Rifaximin Tablets
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Rifaximin Tablets, 550 mg (USRLD: Xifaxan Tablets, 550 mg). Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. Rifaximin tablets will be produced at the Group's manufacturing site at SEZ II, Ahmedabad. Rifaximin tablets had annual sales of USD $2672.9 mn in the United States (IQVIA MAT March 2025).
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Sun Pharma lines up $100 mn to commercialise niche products in FY26
Sun Pharmaceutical Industries has lined up a $100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million. Elaborating on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi said. The drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added.
Economic Times
a day ago
- Economic Times
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. ADVERTISEMENT The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. ADVERTISEMENT In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. ADVERTISEMENT "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. ADVERTISEMENT "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. ADVERTISEMENT Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added. (You can now subscribe to our Economic Times WhatsApp channel)
